Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
NCT03870334 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27
Last updated 2023-12-04
Summary
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study.
Conditions
Interventions
- DRUG
-
BT-11 880 mg
Oral once daily tablet
- DRUG
-
Oral once daily tablet
Sponsors & Collaborators
-
NImmune Biopharma
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-05
- Primary Completion
- 2022-08-26
- Completion
- 2022-08-26
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
NCT01369329 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
NCT01369342 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
NCT00306215 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
NCT03992469 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
NCT02365649 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593 ·Status: RECRUITING ·Phase: PHASE2
-
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
NCT01751152 ·Status: COMPLETED ·Phase: PHASE2
-
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
NCT03395184 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
NCT00130390 ·Status: TERMINATED ·Phase: PHASE2
-
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440385 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
NCT02531113 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT03650413 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
NCT00615199 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
NCT00562887 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
NCT00771667 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
NCT05470985 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097 ·Status: TERMINATED ·Phase: PHASE3
-
Study Evaluating rhIL-11 in Active Crohn's Disease
NCT00040521 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
NCT03599622 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
NCT00265122 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
NCT00032799 ·Status: COMPLETED ·Phase: PHASE3
-
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440372 ·Status: TERMINATED ·Phase: PHASE3
-
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
NCT01635621 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
NCT04102111 ·Status: TERMINATED ·Phase: PHASE2